Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.

Cancer Res Treat · 2024 · PMC11261199 · PMID 38147816

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Besides, randomized PRECIOUS study showed that pertuzumab retreatment in combination with trastuzumab and chemotherapy (TC) significantly improved PFS and showed a trend towards better OS than TC in patients previously treated with pertuzumab [ 10 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.